Status:
NOT_YET_RECRUITING
Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension
Lead Sponsor:
Jing Liu
Conditions:
Hypertension
Eligibility:
MALE
18-60 years
Phase:
PHASE4
Brief Summary
The optimal antihypertensive treatment strategy in young and middle-aged hypertensive adults remains undefined. Clonidine controlled-release patches administered once a week might have the advantage o...
Detailed Description
The young and middle-aged hypertensive population is growing, but the optimal antihypertensive treatment strategy remains undefined. Young and middle-aged adults have poor adherence to antihypertensiv...
Eligibility Criteria
Inclusion
- 18-60 years old male with mild hypertension (systolic blood pressure (BP) 140-159 mmHg and/or diastolic BP 90-99 mmHg).
- History of smoking and a desire to quit.
- Signed informed consent form.
Exclusion
- History of cardiopulmonary and vascular disease.
- Severe liver or kidney disease.
- Night shift workers, drivers, and those who work at height.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT05416840
Start Date
January 1 2024
End Date
December 1 2026
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China, 100044